[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100239650":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":15,"centralContacts":20,"locations":29,"responsibleParty":47,"collaborators":50,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":7,"targetDuration":7,"studyType":65,"phases":7,"briefSummary":66,"conditions":67,"keywords":7,"overallStatus":32,"whyStopped":7,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Augusta University","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","Cannabidiol (Epidiolex)","Daily dosage up to 25 mg\u002Fkg\u002Fday with an optional up titration to a maximal daily dosage up to 50 m\u002Fkg\u002Fday until End of Treatment.",[14],"Epidiolex",[16],{"name":17,"affiliation":18,"role":19},"Yong D Park, MD","Professor","PRINCIPAL_INVESTIGATOR",[21,25],{"name":17,"role":22,"phone":23,"phoneExt":7,"email":24},"CONTACT","706-721-3371","ypark@gru.edu",{"name":26,"role":22,"phone":27,"phoneExt":7,"email":28},"GRU Clinical Trials Office","706-721-9680","ctscto@gru.edu",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Georgia Regents University","AVAILABLE","Augusta","Georgia","30912","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-81.97484,33.47097,{"lat":42,"lon":41},[45,46],{"name":17,"role":22,"phone":23,"phoneExt":7,"email":24},{"name":26,"role":22,"phone":27,"phoneExt":7,"email":28},{"type":19,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Yong Park","Professor Child Neurology, Professor Pediatrics",[51],{"name":52,"class":53},"State of Georgia","UNKNOWN","100239650","epidiolex-and-drug-resistant-epilepsy-in-children-100239650",false,"NCT02397863","Epidiolex and Drug Resistant Epilepsy in Children","An Open Label, Multi-Center Study to Investigate the Safety of Cannabinoid (GWP42003-P) in Children With Medication Resistant Epilepsy","CBD","Inclusion Criteria:\n\n* Patient should have history of trying at least four antiepileptic drugs (AEDs), including one trial of a combination of two concomitant drugs, without successful seizure control. Vagal nerve stimulation, RNS deep brain stimulation, or the ketogenic diet can be considered equivalent to a drug trial.\n* Patient must be taking two or more AEDs at a dose which has been stable for at least four weeks.\n* A State of Georgia resident.\n\nExclusion Criteria:\n\n* Patient is diagnosed as having Dravet Syndrome or Lennox-Gastaut Syndrome and eligible for a GW Pharmaceutical-Sponsored Clinical Trial.\n* Patients who have been part of a clinical trial involving another investigational product in the previous six months.","ALL","1 Year","18 Years","EXPANDED_ACCESS","This open-label, multi-center study is open to patients 1 to 18 years of age at time of enrollment with medication resistant epilepsy.",[68],"Epilepsy","2015-04-23",{"date":71,"type":72},"2015-04-24","ESTIMATED",{"date":74,"type":7},"2014-12",{"date":76,"type":72},"2020-01",{"name":5,"class":6},1]